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Abstract
Background: We examined whether the recent reimbursement reductions on the bone mineral density (BMD) test
affected BMD testing in female Medicare beneficiaries with or without supplemental private health insurance.
Methods: Retrospectively analyzing hospital administrative and clinical data on female Medicare beneficiaries
(n = 1320), we reviewed whether participants received BMD testing before ( January 2004–December 2006) or
after ( January 2007–December 2009) reimbursement reductions for BMD testing. After adjusting for demo-
graphics and clinical characteristics, we performed Cox proportional hazard regression analyses of the BMD test
including data from all study participants; we then performed separate regression analyses using data with or
without supplemental private health insurance.
Results: In those without supplemental private health insurance (n = 421), less frequent BMD testing occurred
after reimbursement reductions for BMD testing (hazard ratio [HR] 0.67, 95% confidence intervals [CI] 0.34-0.98;
p = 0.03). By contrast, in the overall participants (n = 1320) and those with supplemental private health insurance
(n = 899), the number of BMD tests did not change significantly after reimbursement reductions for BMD testing.
Conclusions: We found a significant association between reimbursement reductions and decrease in BMD tests
in female Medicare beneficiaries without supplemental private health insurance.
Introduction
Osteoporosis is characterized by low bone mass andis a progressive, systemic disease that causes bone
fragility and fracture.1–3About one of every two white wo-
men will experience an osteoporosis-related fracture at some
point in her lifetime.2 The number of persons at risk is in-
creasing as the population ages. Detection of osteoporosis
during treatable stages of the disease is optimal; early de-
tection and treatment have been shown to decrease associ-
ated fracture, nursing home placement, and mortality.2–4
Dual-energy x-ray absorptiometry (DXA) is currently the
gold standard for measuring bone mineral density
(BMD).2,4–6 Medicare Part B reimburses DXA coverage once
every 24 months for women who have one or more clinical
risk factors, such as old age.5,6 In agreement with U.S. Pre-
ventive Service Task Force (USPSTF) recommendations, the
National Osteoporosis Foundation (NOF) advises DXA
testing of all women aged ‡ 65 at least once every 24
months.5–7
Since Medicare began to reduce reimbursement for DXA
tests performed in nonhospital settings (e.g., independent
diagnostic facilities and physicians’ offices) from an average
of $139 in 2006 to $72 in 2009, the parallel attenuation of earlier
growth in total number of DXA tests performed at these fa-
cilities has occurred.8–10 Elderly women with higher incomes
or supplemental drug coverage insurance were reported to be
better able to access DXA testing.11 Another study reflecting
the attitudes of private health insurance holders reported that
the use of DXA tests grew at a slower rate since reimburse-
ment cuts for such tests.12 However, no studies examining
how the effects of reimbursement reductions on the use of
DXA vary by supplemental health insurance status have yet
been reported. Elderly women are the most common demo-
graphic group to have osteoporosis and therefore, are ex-
pected to be more vulnerable to reimbursement reductions
than any other age group.2–4 The present study examines
whether the effects of reimbursement reductions on BMD
testing vary by supplemental private health insurance for
female Medicare beneficiaries.
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Study design and study participants
The study site is a U.S. urban nonprofit academic health-
care system. The total study period was 6 years, 3 years before
(phase 1, January 2004–December 2006) and 3 years after
(phase 2, January 2007–December 2009) reimbursement re-
ductions. Because Medicare reimburses DXA test at intervals
of ‡ 2 years and the median intervals between serial DXA
tests were reported to be 2.2 years in the prior literature, we
determined 3 years as the period of each study phase.5,13 In-
clusion criteria were (1) female Medicare Parts A and B ben-
eficiaries (hence, aged ‡ 65) for at least 12 months before study
enrollment, (2) at least one clinic visit before study enrollment
(surrogate marker for continuity of care), and (3) women
without a history of osteoporosis at the time of study enroll-
ment (use of DXA testing for the purpose of osteoporosis
screening).12 Exclusion criteria were (1) residing at a long-
term acute care hospital, skilled nursing facility, adult foster
home, or assisted living facility and (2) either enrolled in
hospice care or with an estimated life expectancy of < 6
months. The sampling strategy was systematic alphabetical
sampling with a random start.14
Administrative claim data were collected from the De-
partment of Medical Operations, which was unaware of
the study objectives and were merged with clinical data by
researchers. Researchers surveyed each participant’s elec-
tronic medical record (EMR) from study enrollment every 90
days in chronologic order. Clinical data from EMRs were
matched with administrative claim data by name and date of
birth. To ensure participant confidentiality, all personal
identifiers were removed from the study databases after
matching was achieved. There was difficulty in interpreting
the statistical analysis because at relatively small numbers
( < 5% of total participants) of Hispanics, Native Americans,
and Asians, and we restricted our analyses to whites and
blacks only and sensitivity analyses of alternative ethnic ca-
tegories.15,16 Missing data accounted for 7% of data values
and were most frequent for amount of education (6%) and
marital status (5%). The number of participants meeting all
eligibility criteria was 1320.
Main outcomes
The main outcomes were (1) whether study participants
received BMD tests at least once during each study period
and (2) where the BMD tests were performed. The method of
BMD testing was DXA testing; the brand and model of DXA
tests were not uniform. DXA testing sites were (1) an inde-
pendent diagnostic testing facility or physician’s office and
(2) a hospital outpatient department. DXA testing included
axial skeleton views of the hip, pelvis, and spine. Other forms
of bone mass measurement (e.g., peripheral skeleton and
quantitative computed tomography) were not considered, as
they are less commonly performed and do not directly reflect
the screening guidelines for osteoporosis.5,10,13 Osteoporosis
prevalence during each period was measured; the definition
of osteoporosis by DXA testing was a T-score of £ - 2.5.2
Osteoporotic women were identified by chronic diseases, in-
cluding generalized, postmenopausal, idiopathic, disuse, and
other osteoporosis, using the International Classification of
Diseases, 9th revision (ICD-9).
Participant characteristics
Participant characteristics were age, ethnicity, education,
marital status, hazardous lifestyle, health insurance, co-
morbidities related to bone health, cognitive impairment, and
home health or day care services. Hazardous lifestyle was
defined as either current smoking or > 7 units of alcohol/
week (1 unit = 14 g of alcohol = 1 glass of wine = 1 pint of
beer = 1 ounce of spirits).17,18 Supplemental private health
insurance is additional out-of-pocket health insurance cover-
age beyond Medicare.11 Supplemental private health insur-
ance included Medicare advantage plus but did not include
dual eligibility for Medicare and Medicaid.
Comorbidities related to bone health included thyroid
hormone supplement or history of hyperthyroidism, any an-
ticonvulsant use, ever use of oral prednisone (5 mg/day for
> 3 months), any immune suppressants, aromatase inhibitor,
antineoplastic chemotherapeutics, history of rheumatoid ar-
thritis, and hyperparathyroidism.2,4 A previous study found
that persons with cognitive impairment were less likely to use
the DXA test.19 To adjust the effects of cognitive impairment
on DXA testing, cognitive information was captured by re-
searchers from either the diagnostic code or the problem list in
EMRs for Alzheimer’s disease, vascular dementia, dementia
with Lewy bodies, dementia with parkinsonism, Pick’s dis-
ease, senile degeneration of the brain, cerebral degeneration,
uncomplicated senile dementia, dementia not otherwise
specified, and cognitive disorder not otherwise specified.
Home health or day care services reflected the need for care-
givers for physically impaired participants. BMD testing was
reported to be also inversely associated with physical dis-
ability.19
For ease of interpretation, characteristics were catego-
rized as age (65–79 and ‡ 80), ethnicity (white and black),
education (high school education or less and high school
graduation or higher), marital status (married and never
married/widowed/divorced), supplemental private health
insurance (yes and no), comorbidities related to bone
health (yes and no), cognitive impairment (yes and no),
and home health or day care services (yes and no).16 The
study was approved by the institutional review board of
Cleveland Clinic Health System. Because data were gen-
erated by reviewing medical records, informed consents
were waived.
Statistical analysis
Bivariate comparisons of participant characteristics and
measured osteoporosis prevalence between study phases
were examined using chi-square tests to compare categorical
data. All reported p values were two-sided throughout, and
p < 0.05 was considered statistically significant. We used Cox
proportional hazards regression models with the BMD test as
the dependable variable to determine the predicted proba-
bility of the BMD test. After adjusting for independent vari-
ables (participant characteristics) by stepwise selection, we
performed Cox proportional hazard regressions of the BMD
test including data from all study participants and then per-
formed separate regression analyses using data with or
without supplemental private health insurance. Backward
and forward selections were examined to ensure that the
methods used for the selection of variables had no impact on
analysis results. Adjusted hazard ratios (HR) of BMD tests
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along with corresponding 95% confidence intervals (CIs) were
derived after adjusting for independent variables. HR > 1 in-
dicated that the predicted probability of the BMD test after
reimbursement reductions was higher than that before reim-
bursement reductions. Sensitivity analyses were used to ex-
plore an alternative category of ethnicity (whites vs. blacks vs.
others). Results for this alternative category are similar to
those of the original category of ethnicity (whites vs. blacks)
and are not included here. All data procedures and analyses
were performed using SAS statistical software version 9.2
(SAS Institute, Cary, NC).
Results
Participant characteristics and main outcomes
Of the total participants (n = 1320), the numbers before
(phase 1) and after (phase 2) reimbursement reductions were
647 and 673, respectively. Table 1 shows the participant char-
acteristics and the main outcomes by study phase. Women
aged ‡ 80 comprised 42% and 45% of the group in phases 1 and
2, respectively. Blacks accounted for 56% in phase 1 and 58% in
phase 2. High school graduation or those with higher educa-
tion represented 43% and 47% in phases 1 and 2, respectively.
Those who never married, were widowed, or were divorced
accounted for 35% and 38% in phases 1 and 2, respectively.
Current smokers and excessive drinkers, representing women
with a hazardous lifestyle, were 12% and 11% in phases 1 and
2, respectively. In phase 1, 67% had supplemental private
health insurance, and 69% in phase 2 had supplemental private
health insurance. In phase 1, 14% had the comorbidities related
to bone health, and in phase 2, 16% had comorbidities related to
bone health. Women with cognitive impairment comprised
15% and 13% of the cohort in phases 1 and 2, respectively.
Those with home health or day care services constituted 24%
and 20% in phases 1 and 2, respectively. Osteoporosis preva-
lence was 14% in phase 1 and 15% in phase 2.
For the main outcomes, 26% and 27% of participants re-
ceived BMD tests at least once during phases 1 and 2, re-
spectively. Among participants receiving BMD tests in phase
1 (n = 168), BMD tests performed at the site of (1) an inde-
pendent diagnostic facility or physician’s office, (2) a hospital
outpatient department, and both (1) and (2) were 71%, 16%,
and 13%, respectively. Among participants receiving BMD
tests in phase 2 (n = 182), BMD tests performed at the site of (1)
an independent diagnostic facility or physician’s office, (2) a
hospital outpatient department, and both (1) and (2) com-
prised 62%, 23%, and 15%, respectively. All participant
characteristics and the main outcomes did not differ signifi-
cantly by study phases except for the study sites of BMD tests
( p = 0.02).
Predicted probability of BMD test: Associations
between study phases and BMD testing in overall
participants and subsets by health insurance
Table 2 presents the results of Cox proportional hazards
regression analyses to determine the predicted probability of
a BMD test with the associations between study phases and
BMD testing in overall participants and subsets by health
insurance. For those without supplemental private health
insurance (n = 421), the adjusted probability of a BMD test in
phase 2 (19%, 95% CI 16%-22%) was lower than that in phase 2
(24%, 95% CI 21%-27%; HR = 0.67, 95% CI 0.34-0.98, p = 0.03).
In the overall participants (n = 1320) and those with supple-
mental private health insurance (n = 899), there was no sig-
nificant difference in the predicted probability of BMD testing
by study phase. Stepwise and backward selections did not
change the results of multivariate regressions. There was no
evidence of multicollinearity or significant interactions be-
tween the variables in regressions, including data from all
study participants and subsets by health insurance status.15
The regressions were assessed with goodness-of-fit testing
procedures, which confirmed that these were not violated.15
Table 1. Participant Characteristics and Main Outcomes by Study Phases
Characteristics, % (n)
Phase 1, n = 647
Before reimbursement cuts
Phase 2, n = 673
After reimbursement cuts pa
Age, ‡ 80 42 (272) 45 (302) 0.41
Ethnicity, black 56 (362) 58 (390) 0.57
High school graduate or more 43 (279) 47 (316) 0.28
Never married, widowed, or divorced 35 (227) 38 (256) 0.36
Hazardous lifestyle 12 (77) 11 (75) 0.13
Health insurance; supplementary private insurance 67 (434) 69 (465) 0.68
Comorbidities related to bone health 14 (91) 16 (108) 0.47
Cognitive impairment 15 (97) 13 (87) 0.63
Home health or day care services 24 (156) 20 (134) 0.12
Osteoporosis prevalence 14 (91) 15 (101) 0.62
Main outcomes, % (n) Phase 1, n = 647 Before
reimbursement cuts
Phase 2, n = 673 After
reimbursement cuts
pa
Number of participants receiving BMD test at least once 26 (168) 27 (182) 0.59
Among participants receiving BMD test at least once Phase 1, n = 168 Phase 2, n = 182
Study sites
A. Independent diagnostic facility or physician’s office 69 (116) 62 (113) 0.02
B. Hospital outpatient department 18 (30) 23 (42)
Both A and B 13 (22) 15 (27)
p values were derived from bivariate comparisons of participant characteristics and the main outcomes by study phase.
BMD, bone mineral density.
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Discussion
Although the overall number of BMD tests was not affected
after the reimbursement reductions, the results indicated that
certain groups without supplemental private health insurance
used the BMD test at a significantly lower rate since the reim-
bursement reductions. Consistent with nationally representa-
tive reports on osteoporosis screening for older adults, less than
a third of study participants in the present study had a DXA test
in 3 years.8,9,13 BMD testing rates in the present and prior studies
are much lower than those of other screening services for older
women, such as mammography, where two thirds of eligible
populations were tested within the past 2 years.3,20 BMD testing
rates for the purpose of osteoporosis prevention may vary by
patient demographics. For example, although performed at
academic health centers similar to those in the present study,
BMD testing rates performed at facilities with predominantly
white population are substantially higher (64%-70% in the past 3
years) than those in the present study.19,21
Consistent with prior investigations of sites that perform
DXA tests, the shift in BMD testing from nonhospital settings
(e.g., physicians’ offices and independent diagnostic facilities)
to hospital settings was observed in the present study.8,10
Several lines of evidence reflecting physicians’ attitudes to-
ward the reimbursement cuts in DXA testing have shown that
more than a third of physicians reduced the number of DXA
tests and opted to stop investing in DXA machines for their
offices.8,9,12,22 Reimbursement reductions for DXA tests in
nonhospital settings appear to be closely linked to the phy-
sicians’ attitudes. Although the Affordable Care Act of 2010
partially restored Medicare payment during 2010 and 2011,
the shift in DXA test sites is expected to continue.8,22
To our knowledge, the present study is the first to examine
the effects of supplemental private health insurance on the re-
lationship between reimbursement reductions for DXA testing
and the BMD testing rate for female Medicare beneficiaries.
Prior studies have shown that suboptimal DXA testing was
associated with lower use of osteoporosis treatment, which
suggests that those who carry supplemental health insurance
may be better able to afford osteoporosis management op-
tions.5,11,23 Having supplemental health insurance in addition to
Medicare may make it easier for Medicare beneficiaries to afford
their various healthcare needs related to osteoporosis (e.g., more
frequent physician office visits, switching from generic to brand
name medications) because of lower copayments than those
Medicare-only beneficiaries might be expected to pay.
The use of DXA testing as an osteoporosis screening tool has
been reported to be a marker for interest level in osteoporosis
management.1,2,11 The decreased use in DXA tests may raise
concerns that patients and physicians are paying little attention
to osteoporosis management. Although Medicare covers DXA
testing every 2 years (or more frequently if necessary), DXA
testing was more accessible to beneficiaries with supplemental
health insurance than to those without such insurance.
Our findings highlight the urgent need for public attention
to resolve the disparity in access to osteoporosis screening by
health insurance type; similar disparities in diverse public
health services across acute and chronic disease care have
been reported.23–25 In addition, preventing osteoporotic frac-
ture through DXA testing in older women has been shown to
be associated with lower likelihood of nursing home admis-
sion, higher quality of life, and reductions in public financial
burden. Therefore, the resulting decrease in BMD testing be-
cause of a lack of supplemental private health insurance is
likely to cause a lower quality of care.2–4,8,12,22
We acknowledge several limitations to the study design. Be-
cause data collection was limited in a U.S. urban area and distinct
racial composition (blacks representing more than half of the
participants), the study cannot be generalized to other areas or
populations. Furthermore, the use of secondary data may have
led to observer variation in clinical data from EMRs. About 7% of
data were missing, and data from other health systems and
physician characteristics were not included in the analysis;
therefore, selection bias may have occurred. Other than health
insurance status, information representing socioeconomic status
(e.g., annual income) and physician characteristics were not in-
cluded; for this reason, examining the internal consistency of our
findings was also limited. Therefore, our findings should be in-
terpreted with caution and considered preliminary until they are
confirmed in future studies with more representative data.
Conclusions
We found a significant association between reimbursement
reductions and decrease in BMD testing in female Medicare
beneficiaries without supplemental private health insurance.
Table 2. Predicted Probability of Bone Mineral Density Test: Associations Between Study Phase
and Bone Mineral Density Testing in Overall Participants and Subsets by Health Insurance
Predicted probability of BMD
test, % (95% CI)
Participant population Phase 1 Phase 2
Hazard ratioa
(95% CI) p
Overall participants (n = 1320) 26 (21-32) 27 (22-33) 1.04 (0.62-1.49) 0.64
n = 647 n = 673
Subset by health insurance
Participants with supplementary private insurance 28 (24-32) 30 (26-35) 1.08 (0.71-1.52) 0.41
(n = 899) n = 434 n = 465
Participants without supplementary private insurance 24 (21-27) 19 (16-22) 0.67 (0.34-0.98) 0.03
(n = 421) n = 213 n = 208
aHazard ratios were derived from Cox proportional hazard regressions after adjusting for participant characteristics (age, ethnicity,
education, marital status, hazardous lifestyle, health insurance, comorbidities related to bone health, cognitive impairment, and home health
or day care services). Hazard ratio > 1 indicates the predicted probability that the BMD test in phase 2 was higher than that in phase 1.
CI, Confidence interval.
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